Syngenta's $66 Billion Ask Puts 15x EBITDA on Ag Chem While Corteva Trades at 3x

The number to argue about is $66 billion, not $88 billion. $66 billion is 15 times the $4.4 billion of EBITDA Syngenta reported for 2025, which makes it the minimum the advisers say they will accept; the $88 billion implied by 20 times is what a seller hopes for. Meanwhile the base year is shrinking underneath the multiple: first-half 2026 sales fell 7% at constant exchange rates, second-quarter sales of $5.7 billion fell 10% at constant rates, and China sales fell 15%.

The path here has been long and-slipping. A $9 billion Shanghai listing was withdrawn in 2024 after two years of review, a $10 billion Hong Kong plan slipped from the first quarter into the second half of 2026, and Bloomberg reported in July that the deal was pushed toward 2027 pending better sector conditions and regulatory progress. The valuation ask rose while the timetable slipped, which is the tell that this is a seller looking for a market rather than a company timing its moment.

The $66 billion is an enterprise value, because the number is applied to EBITDA. Strip out Syngenta's $9.5 billion of net debt and the equity is worth roughly $56.5 billion; at 20 times EBITDA it is worth about $78.5 billion. That distinction sets the float: a 10% to 20% sale of a $56.5 billion equity base is $5.7 billion to $11.3 billion, which brackets the reported $5 billion to $10 billion offering almost exactly.

The balance sheet is the second reason this deal can happen at all. Net debt of 2.2 times EBITDA and 130% of equity leaves Syngenta with a thin capital base nine years after a debt-funded take-private, and Reuters reports that proceeds are earmarked for reducing debt. Apply $10 billion to the balance sheet and net debt falls to roughly zero, which turns this listing into a deleveraging event as much as a fundraising one. The 2017 buyer is repairing the balance sheet at public-market prices.

Compare the ask with how the listed ag-input complex is actually priced. On trailing twelve-month EBITDA, Corteva trades near 3 times and FMC has negative trailing EBITDA, while Nutrien sits at 7 times and CF Industries under 5. Yangnong Chemical, China's largest crop-protection exporter and the closest listed analogue to Syngenta's crop-protection business, trades at 11 times. Syngenta is asking for two to five times what its own peers command.

Two caveats, both material. Corteva completed its separation on October 1, 2026 into New Corteva for crop protection and Vylor for seed and genetics, so its 3 times is a blend of two companies that will now be valued apart. And FMC is the honest counterexample to the entire sector: with trailing EBITDA of minus $387 million against $4.3 billion of gross debt, its $577 million of market value is an option on a restructuring rather than an earnings stream.

The numbers behind Corteva's discount are stark. Its market value of about $8 billion sits barely above its tangible book of roughly $7 billion, once $18.4 billion of goodwill and intangibles are stripped out of $25.2 billion of equity, and it earned $3.85 billion of operating EBITDA in 2025 on $17.4 billion of sales. A market that refuses to pay more than 3 times for that franchise is telling investors that mid-cycle ag earnings power has been permanently repriced, not temporarily depressed.

The obvious objection is that Syngenta deserves better than Corteva or FMC because it is the largest ag-technology company by revenue, with a 19.5% first-half EBITDA margin and a China volume base no Western peer has. The financials do not support quality as the explanation for the discount. Nutrien earns a 22% EBITDA margin and trades at 7 times. ADM earns less than 5% and trades at 10 times. CF Industries earns more than 50% and trades under 5 times.

Quality is being ignored; what the market is pricing is cycle risk, and the cycle is ugly. Corteva's crop-protection price fell 4% in the second quarter with volume down 2% and seed volume down 3%, and Syngenta's own North American sales fell 4% with North American seed sales down 13%. Fertilizer is the exception: Nutrien raised 2026 potash volume guidance to 14.2 million to 14.8 million tonnes, and CF Industries sold 15% less nitrogen in the second quarter while revenue rose to $2.22 billion from $1.89 billion.

That is why this is a sector event and not a company event. A public market willing to pay 15 to 20 times for the number-one global platform in this business has just told every other ag-input equity what its assets are worth. If the book builds at the floor, the discount across the complex was a mispricing. If it prices at 4 or 5 times, the market was right, and the sellers are the ones paying.

Hong Kong's IPO market has been the best in the world for two years and is getting harder. The city raised HK$209.9 billion across 85 IPOs in the first half of 2026, its strongest first half in five years, and the average first-day return was 61%. But cornerstone investors are pulling back, which is forcing some issuers to trim deal sizes, and a record wave of lock-up expiries is about to hit the market. Syngenta would be the largest deal since 2010, and the largest deal in a market where the marginal buyer's enthusiasm is the variable.

The failure mode is arithmetic. Peer multiples of 4 to 7 times on trailing EBITDA of roughly $4.5 billion imply an enterprise value of $18 billion to $32 billion. If Syngenta's advisers meet the market somewhere in that band instead of at the $66 billion floor, the gap between the ask and the tape is $34 billion to $48 billion of enterprise value, the state's exit shrinks to roughly a third of what was planned, and the whole ag-input complex gets its answer in the wrong direction.

The stakes for the food chain run through fertilizer, and 2026 has been a repricing year. China spent the year restricting exports of key fertilizers, extended phosphate export curbs through August, and reopened urea in May with a $660 a tonne minimum export price, while the Iran conflict disrupted trade in crop nutrients. Chinese domestic urea prices stayed well below global levels precisely because the export restrictions held back supply.

The farm sector is absorbing it. USDA now sees 2026 net farm income of $158.4 billion, down 2.6%, and real net cash farm income down 2.5%, even though crop cash receipts rise 6.1% on corn up 11.3% and soybeans up 10.0%. Growers are getting more for their crops and paying more for the inputs that grow them. That is exactly the environment in which crop-protection volumes shrink, and both Corteva's4% price decline and Syngenta's 4% North American sales decline sit inside it.

This is where the multiple and the macro meet. A 15-times-plus listing funds research and balance-sheet repair for the company best placed to keep pricing in a scarce-input world, and that pricing eventually shows up in food prices with a lag. The counterargument is stronger: the same multiple assumes growers absorb higher input costs indefinitely, and they are already cutting crop-protection volumes rather than paying more. A 15-times multiple on shrinking volume is a bet that the volume returns, not a bet that price sticks.

Inside China, Syngenta's own numbers show what a 15-times multiple has to be built on. China unit sales fell 15% in the first half, but the decline came from exiting low-margin grain trading, optimizing the MAP business and deconsolidating Sinofert in January. Underneath, branded formulation grew 15%, seeds grew 4% and Yangnong Chemical grew 12% inside China, while group crop-protection sales in China grew 20%. The group is shrinking its China revenue and raising its China quality at the same time.

Yangnong is the tell. Revenue rose 13.8% to ¥11.87 billion in 2025 and net profit rose 7% to ¥1.29 billion, but trailing EBITDA has fallen to ¥1.97 billion from ¥2.37 billion, so volumes are still growing while prices fall. That is the mechanism that eventually breaks any Western pricing umbrella, and it is also why 11 times is the most likely landing zone for a Chinese asset valued in a Chinese market. A successful Hong Kong listing would hand local investors a 15-times benchmark for assets they currently pay 11 times for, and the read-across would run through Yangnong's valuation before it reaches Corteva's.

Over the next two quarters the sequence is mechanical. Corteva begins reporting as two companies, Nutrien and CF Industries print realized fertilizer prices that reset the 2027 input-cost base, and Syngenta's filing becomes public, which is the moment the multiple stops being an adviser's anchor and becomes a document with a prospectus attached. The first hard test is the book: cornerstone commitments and pricing guidance in the launch.

Over one to three years, the question is whether a state-backed, capital-light platform can hold pricing power through a farm-income squeeze that has already cut real net cash farm income 2.5%. The bull case is that Syngenta's 1.9% capital intensity and China volume base make it the last independent global platform, and a 15-times listing resets every ag-input multiple in the sector. The bear case is that Chinese capacity keeps taking price, that fertilizer's price spike unwinds when China's export restrictions ease, and that the complex settles at 4 to 6 times, with Syngenta the last to admit it.